In addition, in the TCGA cohort, patients with pan-gliomas, IDH mutant and IDH wildtype in the low-risk group also tended to have longer PFS than patients in the high-risk group (Figure 4E and Supplementary Figure 3G, 3H), and the risk score can also effectively predict the 1, 3, 5-year PFS rate of patients with pan-gliomas, IDH mutant and IDH wildtype (Figure 4G, and Supplementary Figure 3I, 3J and Supplementary Table 6). The gene discussed is IDH1; the disease is central nervous system cancer.